Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. Min H, Morony S, Sarosi I, et al. J Exp Med 192: 463-474, 2000. PMID: 10952716

OPG inhibits vascular calcification and does not increase atherosclerosis in hyperlipidemic LDL receptor knockout mice. Morony S, Zhang Z, Cattley R, Dwyer D, Stolina M, Kostenuik PJ, Tintut Y, and Demer L. J Bone Miner Res 21 (Suppl. 1): S78, 2006 (Abstract)

RANKL infusion as a disease model: Implications for bone and vascular systems. Yuan YY, Kostenuik PJ, Morony S, Simionescu DT, Basalyga DM, Bateman TA. J Bone Miner Res 21

(Suppl. 1): S163, 2006 (Abstract)

 Vascular calcification and aortic gene expression are consistent with hyperphosphatemia in OPG-Deficient Mice. Morony S, Zhang Z, Tintut Y, KostenuikPJ, Demer LL. J Bone Miner Res 22 (Suppl. 1): S34, 2007 (Abstract)

Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Morony S, Tintut Y, Zhang Z, Cattley RC, Dwyer D, Stolina M, Kostenuik PJ, and Demer LL. Circulation 117: 411-420, 2008. PMID: 18172035

Inhibition of receptor activator of NF-κB ligand by denosumab attenuates vascular calcium deposition in mice. Helas S, Goettsch C, Schoppet M, et al. Am J Pathol 175: 473-478, 2009.

PMID: 19590040

​Selective inhibition of receptor activator of NF-κB ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction. Slavic S, Andrukhova O, Ford K, Handschuh S, Latic N, Reichart U, Sasgary S, Bergow C, Hofbauer LC, Kostenuik PJ, Erben RG.  J Mol Med. 2018 May 8. doi: 10.1007/s00109-018-1641-x. PubMed PMID: 29736604

Why is hypercholesterolemia so prevalent? A view from evolutionary medicine. Laufs U, Dent R, Kostenuik PJ, Toth PP, Catapano A, and Chapman MJ.   Eur Heart J 2018 Aug 28. doi: 10.1093/eurheartj/ehy479. PMID: 30169643

​

Some of Dr. Kostenuik's publications in the cardiovascular field:

As a PhD student in the McMaster University Hospital's Department of Hemostasis, Thrombosis and Atherosclerosis, Paul was introduced to vascular biology via the role of integrins in tumor cell adhesion to endothelial cells. During his industry career he collaborated on vascular calcification and myocardial infarction projects, and was privileged to co-author a perspective on hypercholesterolemia with some of Europe's top cardiologist KOLs (published in the European Heart Journal; PMID: 30169643). As CEO and co-founder of the orthobiologics start-up Ortheus Inc, Dr. Kostenuik leveraged his understanding of blood coagulation to develop enhanced fibrin-based gels for drug-eluting bone graft substitutes, for which an international patent was recently issued  (https://patents.google.com/patent/WO2022125536A1/en).

Cardiovascular

Cardiovascular